Search Within

Diana E Lake

Formats
  1. Meeting Abstract (48)
  2. Journal Article (39)
  3. Book Whole (1)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (89)
  2. Department of Medicine (89)
  3. Solid Tumor Oncology Division (89)
  4. Survivorship Research (89)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (48)

More Groups

People
  1. Clifford Hudis (65)
  2. Larry Norton (45)
  3. Gabriella D'Andrea-Carlino (39)
  4. Chau Dang (37)
  5. Monica Fornier (36)
  6. Maura Dickler (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (4)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Cancer Research (16)
  3. Breast Cancer Research and Treatment (13)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (20)
  3. Springer (14)
  4. Elsevier Inc. (9)
  5. Oxford University Press (3)
  6. American Medical Association (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Theodoulou, M.; Traina, T. A.; Dugan, U.; Lake, D.; Fornier, M.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Dx/Rx: Breast cancer
    Book Whole

    Lake, D.
    Jones and Bartlett Publishers (2006)

    Fulltext@MSK | Save
  • A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)
    Meeting Abstract

    Sugarman, S. M.; Wasserheit, C.; Hodgman, E.; Coglianese, M. E.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Study participants' perceptions of the process and impact of receiving results of N9831
    Meeting Abstract

    Partridge, A. H.; Wolff, A. C.; Marcom, P. K.; Kaufman, P. A.; Moore, C.; Lake, D.; Fleming, G.; Rugo, H. S.; Collyar, D.; Winer, E. P.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Norton, L.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)
    Meeting Abstract

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save